Epithelial Ion Transport Defects in Pancreatitis: establishment of an organoid model

Epithelial Ion Transport Defects in Pancreatitis: establishment of an organoid model - C-PIE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52348

Enrollment

Registered

2022-02-11

Start date

2022-06-14

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic pancreatitis inflammation of the pancreas

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: A subject must meet all of the following criteria: - Must be an adult (>18 years old) - Must be undergoing pancreatoscopy within the framework of regular diagnostics or treatment in the Erasmus MC - Must sign informed written consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Assess the ability to culture PDEC organoids from pancreatic duct microbiopsies, to study the pathophysiology and pharmacotherapy of pancreatitis in vitro.	—

Secondary

Measure	Time frame
• Asses the phenotype of PDEC organoids derived from pancreatitis patients, as compared to those derived from non-pancreatitis patients, by investigation of: o Genetic makeup o Gene and protein expression o Ion transport o Response to known pancreatitis-inducers and/or ion transport modulators, to further elucidate the molecular mechanisms involved in the disruption of CFTR function in PDECs in pancreatitis and potentially to advance the development of pharmacotherapy for pancreatitis. • Assess the ability of duodenal organoids to mimic key features of ion transport in PDEC organoids, to explore a more readily accessible surrogate model to study the pathophysiology and pharmacotherapy of pancreatitis in vitro.	—

Measure

Time frame

• Asses the phenotype of PDEC organoids derived from pancreatitis patients, as compared to those derived from non-pancreatitis patients, by investigation of: o Genetic makeup o Gene and protein expression o Ion transport o Response to known pancreatitis-inducers and/or ion transport modulators, to further elucidate the molecular mechanisms involved in the disruption of CFTR function in PDECs in pancreatitis and potentially to advance the development of pharmacotherapy for pancreatitis. • Assess the ability of duodenal organoids to mimic key features of ion transport in PDEC organoids, to explore a more readily accessible surrogate model to study the pathophysiology and pharmacotherapy of pancreatitis in vitro.

—

Countries

Netherlands

Outcome results